DE122006000005I1 - Verk}rzter Keratinocyten-Wachstumsfaktor(KGF) mit erh¦hter biologischer Aktivit{t - Google Patents

Verk}rzter Keratinocyten-Wachstumsfaktor(KGF) mit erh¦hter biologischer Aktivit{t

Info

Publication number
DE122006000005I1
DE122006000005I1 DE1994634053 DE69434053C DE122006000005I1 DE 122006000005 I1 DE122006000005 I1 DE 122006000005I1 DE 1994634053 DE1994634053 DE 1994634053 DE 69434053 C DE69434053 C DE 69434053C DE 122006000005 I1 DE122006000005 I1 DE 122006000005I1
Authority
DE
Germany
Prior art keywords
increased
kgf
keratinocyte growth
growth factor
biological activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE1994634053
Other languages
English (en)
Other versions
DE69434053T2 (de
DE122006000005I2 (de
DE69434053D1 (de
Inventor
J Gospodarowicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE122006000005I1 publication Critical patent/DE122006000005I1/de
Publication of DE122006000005I2 publication Critical patent/DE122006000005I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE1994634053 1993-06-29 1994-04-28 Verk}rzter Keratinocytenwachstumsfaktor (kgf) mit erh¦hter Biologischer aktivit{t Active DE122006000005I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
PCT/US1994/004694 WO1995001434A1 (en) 1993-06-29 1994-04-28 A truncated keratinocyte growth factor (kgf) having increased biological activity

Publications (2)

Publication Number Publication Date
DE122006000005I1 true DE122006000005I1 (de) 2006-08-10
DE122006000005I2 DE122006000005I2 (de) 2006-11-23

Family

ID=22198501

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69434053T Expired - Lifetime DE69434053T2 (de) 1993-06-29 1994-04-28 Verkürzter keratinocytenwachstumsfaktor(kgf)mit erhöhter biologischer aktivität
DE1994634053 Active DE122006000005I2 (de) 1993-06-29 1994-04-28 Verk}rzter Keratinocytenwachstumsfaktor (kgf) mit erh¦hter Biologischer aktivit{t

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69434053T Expired - Lifetime DE69434053T2 (de) 1993-06-29 1994-04-28 Verkürzter keratinocytenwachstumsfaktor(kgf)mit erhöhter biologischer aktivität

Country Status (25)

Country Link
US (7) US5677278A (de)
EP (2) EP1493812A3 (de)
JP (4) JP3570516B2 (de)
KR (1) KR960703433A (de)
CN (1) CN1129955A (de)
AT (1) ATE278777T1 (de)
AU (1) AU681405B2 (de)
BG (1) BG100236A (de)
BR (1) BR9407035A (de)
CA (1) CA2166278A1 (de)
CZ (1) CZ343795A3 (de)
DE (2) DE69434053T2 (de)
DK (1) DK0706563T3 (de)
ES (1) ES2227527T3 (de)
FI (1) FI956203A (de)
FR (1) FR06C0004I2 (de)
HU (1) HUT73453A (de)
LU (1) LU91215I2 (de)
NL (1) NL300217I2 (de)
NO (1) NO955189L (de)
NZ (1) NZ266622A (de)
PL (1) PL312257A1 (de)
PT (1) PT706563E (de)
SK (1) SK153295A3 (de)
WO (1) WO1995001434A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE197800T1 (de) 1989-01-31 2000-12-15 Jeffrey S Rubin Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
US5814605A (en) * 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
JP3570516B2 (ja) * 1993-06-29 2004-09-29 カイロン コーポレイション 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
CA2201762C (en) * 1994-10-13 2001-12-18 Eric W. Hsu Method for purifying keratinocyte growth factors
CZ297329B6 (cs) * 1994-10-13 2006-11-15 Amgen Inc. Analog nativního keratinocytového rustového faktoru kovalentne pripojený k polyethylenglykolu nebo príbuznému vodorozpustnému organickému polymeru, jeho pouzití a in vitro zpusob stimulace produkce nefibroblastových epithelových bunek
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ES2293137T3 (es) 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
ATE263239T1 (de) * 1996-10-15 2004-04-15 Amgen Inc Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
CA2294569A1 (en) * 1997-06-19 1998-12-23 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
NZ505324A (en) 1997-12-22 2002-11-26 Human Genome Sciences Inc Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration
EP1054900A4 (de) * 1998-02-13 2004-12-22 Human Genome Sciences Inc Therapeutische verwendungen des keratinozten wachstumsfaktors-2
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
US6485937B1 (en) 1999-10-15 2002-11-26 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
WO2002042336A2 (en) 2000-11-21 2002-05-30 The Texas A & M University System Fgf-affinity chromatography
EP1357931A2 (de) * 2001-01-08 2003-11-05 Human Genome Sciences, Inc. Keratinozyt-wachstumsfaktor-2
CA2438652A1 (en) 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
JP2005500390A (ja) 2001-08-21 2005-01-06 カイロン コーポレイション Ｋｇｆポリペプチド組成物
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
RS53548B1 (en) * 2004-12-15 2015-02-27 Swedish Orphan Biovitrum Ab (Publ) THERAPEUTIC FORMULATIONS OF KERATINocyte GROWTH FACTORS
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
EP1969001A2 (de) * 2005-11-22 2008-09-17 Novartis Vaccines and Diagnostics, Inc. Norovirus- und sapovirus-antigene
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
EP4219708A3 (de) 2009-07-17 2023-10-11 Aaron Thomas Tabor Zusammensetzungen und verfahren zur genetischen modifikation von zellen mit kosmetischer funktion zur verbesserung des kosmetischen erscheinungsbildes
RU2016117275A (ru) 2013-11-01 2017-12-04 Сфериум Биомед С.Л. Тельца включения для трансдермальной доставки терапевтических и косметических средств
CN117858717A (zh) 2021-08-30 2024-04-09 联合化学实验室有限公司 用于治疗炎症性疾病的蛋白质组合物
KR20230070596A (ko) * 2021-11-15 2023-05-23 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE197800T1 (de) * 1989-01-31 2000-12-15 Jeffrey S Rubin Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5814605A (en) 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
JP3570516B2 (ja) 1993-06-29 2004-09-29 カイロン コーポレイション 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）
CZ297329B6 (cs) 1994-10-13 2006-11-15 Amgen Inc. Analog nativního keratinocytového rustového faktoru kovalentne pripojený k polyethylenglykolu nebo príbuznému vodorozpustnému organickému polymeru, jeho pouzití a in vitro zpusob stimulace produkce nefibroblastových epithelových bunek
DE69530404T2 (de) 1994-10-13 2003-11-13 Amgen Inc Analogen des keratinozytenwachstumfaktors

Also Published As

Publication number Publication date
JP3570516B2 (ja) 2004-09-29
EP0706563B1 (de) 2004-10-06
BR9407035A (pt) 1996-03-12
FR06C0004I1 (de) 2006-03-10
BG100236A (en) 1996-07-31
HUT73453A (en) 1996-08-28
ES2227527T3 (es) 2005-04-01
LU91215I2 (en) 2006-03-27
JPH09500267A (ja) 1997-01-14
FI956203A0 (fi) 1995-12-22
US6677301B1 (en) 2004-01-13
US5843883A (en) 1998-12-01
PL312257A1 (en) 1996-04-01
NO955189D0 (no) 1995-12-20
CZ343795A3 (en) 1996-07-17
NO955189L (no) 1995-12-20
ATE278777T1 (de) 2004-10-15
DE69434053T2 (de) 2006-02-23
HU9503857D0 (en) 1996-02-28
CN1129955A (zh) 1996-08-28
JP2009062396A (ja) 2009-03-26
US6074848A (en) 2000-06-13
AU6820894A (en) 1995-01-24
NL300217I1 (nl) 2006-04-03
JP2006075173A (ja) 2006-03-23
JP4662569B2 (ja) 2011-03-30
WO1995001434A1 (en) 1995-01-12
DE122006000005I2 (de) 2006-11-23
US20090093400A1 (en) 2009-04-09
US5677278A (en) 1997-10-14
AU681405B2 (en) 1997-08-28
EP0706563A1 (de) 1996-04-17
CA2166278A1 (en) 1995-01-12
EP1493812A2 (de) 2005-01-05
DE69434053D1 (de) 2005-01-20
US5863767A (en) 1999-01-26
JP2004166709A (ja) 2004-06-17
FI956203A (fi) 1996-02-07
KR960703433A (ko) 1996-08-17
SK153295A3 (en) 1996-11-06
NZ266622A (en) 1997-10-24
US5773586A (en) 1998-06-30
PT706563E (pt) 2005-01-31
FR06C0004I2 (fr) 2006-12-29
EP1493812A3 (de) 2006-02-08
DK0706563T3 (da) 2005-01-31
NL300217I2 (nl) 2006-05-01

Similar Documents

Publication Publication Date Title
DE122006000005I2 (de) Verk}rzter Keratinocytenwachstumsfaktor (kgf) mit erh¦hter Biologischer aktivit{t
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
WO1990013306A3 (en) Small polypeptides
AU8033991A (en) Novel isolate of trichoderma, fungicidal compositions containing said isolate and use against b. cinerea and s. sclerotiorum
AU5865290A (en) Modified biologically active protein
ATE166359T1 (de) Peptide mit einer lanthionin-brücke
DE69126049T2 (de) Vektoren und Zusammensetzungen zur Expression von Glykosilationsmutanten des menschlichen Proteins-C
AU3095892A (en) Human type antibody reactive with GPIIb/IIIa
DE59409964D1 (de) Rekombinante D-Hydantoinase, Verfahren zur Herstellung und Verwendung
AU4064293A (en) Textile material
DE69306273T2 (de) Mitogen für die glatte Muskulatur und dessen kodierende DNS
EP0206329A3 (en) Sprung floor
DE69529405D1 (en) Pd-ecgf / thymidin phosphorylase spezifischer monoklonaler antikörper
AU1305097A (en) Protein induced by deprenyl$m(3)
Domino et al. Ain't that a Shame
IT9021117V0 (it) Leva di comando particolarmente per l'azionamento di gruppi valvolari
ATE290598T1 (de) Neue staphylokinase derivate
CA2118207A1 (en) Bacillus thuringiensis m200 for the biological control of agricultural and horticultural entomological pests
TH22943A (th) รีคอมบิแนนท์โปรตีนที่กำหนดเป็น dev-1 ที่มีประโยชน์สำหรับตรวจหา hiv ลำดับดีเอนเอที่ประมวลรหัสของโปรตีนและการวิเคราะห์ทางอิมมูนโดยใช้โปรตีนนี้